Zenox, I take it you are talking about LNA043 when
you mention Novartis may receive regulatory
approval before iPPS for OA. Funny how I
was given the cold shoulder when I explored
the proposition that it may be stiff competition.
If you are not talking about LNA043, then I
withdraw the remark.
Ann: Paradigm AGM Presentation, page-95
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |